Mercer Capital's Laboratory Services Industry newsletter provides perspective on valuation issues. Each newsletter also includes a macroeconomic trends, industry trends, and guideline public company metrics.
Mercer Capital's Value Focus: Laboratory Services | Mid-Year 2018Mercer Capital
Mercer Capital's Laboratory Services Industry newsletter provides perspective on valuation issues. Each newsletter also includes macroeconomic trends, industry trends, and guideline public company metrics.
Mercer Capital's Value Focus: Laboratory Services | Mid-Year 2014Mercer Capital
Mercer Capital's Laboratory Services Industry newsletter provides perspective on valuation issues. Each newsletter also typically includes a macroeconomic trends, industry trends, and guideline public company metrics.
This document provides an overview and analysis of financialization in the pharmaceutical industry, using Pfizer's attempted takeover of AstraZeneca as a case study. It finds that the erosion of the blockbuster drug model due to patent expirations, increasing costs, and regulatory pressures has reduced profitability and led pharmaceutical companies to pursue mergers and acquisitions to meet shareholder demands for returns. While M&As provide short-term growth, they may undermine long-term R&D productivity and threaten high-skilled jobs in the UK, as demonstrated by the Pfizer-AstraZeneca deal. The UK government has an obligation to consider the impact on domestic employment.
Mercer Capital's Value Focus: Laboratory Services | Year-End 2014Mercer Capital
Mercer Capital's Laboratory Services Industry newsletter provides perspective on valuation issues. Each newsletter also includes a macroeconomic trends, industry trends, and guideline public company metrics.
International Journal of Pharmaceutical Science Invention (IJPSI) is an international journal intended for professionals and researchers in all fields of Pahrmaceutical Science. IJPSI publishes research articles and reviews within the whole field Pharmacy and Pharmaceutical Science, new teaching methods, assessment, validation and the impact of new technologies and it will continue to provide information on the latest trends and developments in this ever-expanding subject. The publications of papers are selected through double peer reviewed to ensure originality, relevance, and readability. The articles published in our journal can be accessed online.
This document provides estimates of medical device spending in the United States from 1989-2009. The key findings are:
1) Medical devices accounted for 5.9% of total national health expenditures in 2009, totaling $147 billion. This share has remained relatively constant since 1992, ranging from 5.3-6%.
2) Medical device price increases have consistently been lower than other medical prices and inflation, averaging 1% annually compared to 4.7% for medical care prices and 2.8% for overall inflation.
3) While medical device spending has increased slightly faster than overall health spending, the constant share of total spending and slower price increases suggest medical devices have not been major drivers of rising healthcare costs in the
Reforming GxP for Today and Tomorrow- Philadelphia, PA meetingDemet G. Sag
Reforming GxP for today and tomorrow
The general issues
Imports vs Safety
Driving market & business
II. Global Impact Factors
Regulation Strategies
III. Development of Education Program &Training
Survey of likely 2014 likely voters in Arkansas, Colorado, Georgia, Kentucky, Louisiana, Michigan, Montana and North Carolina measuring opinion of the proposed EPA carbon emissions regulations.
Mercer Capital's Value Focus: Laboratory Services | Mid-Year 2018Mercer Capital
Mercer Capital's Laboratory Services Industry newsletter provides perspective on valuation issues. Each newsletter also includes macroeconomic trends, industry trends, and guideline public company metrics.
Mercer Capital's Value Focus: Laboratory Services | Mid-Year 2014Mercer Capital
Mercer Capital's Laboratory Services Industry newsletter provides perspective on valuation issues. Each newsletter also typically includes a macroeconomic trends, industry trends, and guideline public company metrics.
This document provides an overview and analysis of financialization in the pharmaceutical industry, using Pfizer's attempted takeover of AstraZeneca as a case study. It finds that the erosion of the blockbuster drug model due to patent expirations, increasing costs, and regulatory pressures has reduced profitability and led pharmaceutical companies to pursue mergers and acquisitions to meet shareholder demands for returns. While M&As provide short-term growth, they may undermine long-term R&D productivity and threaten high-skilled jobs in the UK, as demonstrated by the Pfizer-AstraZeneca deal. The UK government has an obligation to consider the impact on domestic employment.
Mercer Capital's Value Focus: Laboratory Services | Year-End 2014Mercer Capital
Mercer Capital's Laboratory Services Industry newsletter provides perspective on valuation issues. Each newsletter also includes a macroeconomic trends, industry trends, and guideline public company metrics.
International Journal of Pharmaceutical Science Invention (IJPSI) is an international journal intended for professionals and researchers in all fields of Pahrmaceutical Science. IJPSI publishes research articles and reviews within the whole field Pharmacy and Pharmaceutical Science, new teaching methods, assessment, validation and the impact of new technologies and it will continue to provide information on the latest trends and developments in this ever-expanding subject. The publications of papers are selected through double peer reviewed to ensure originality, relevance, and readability. The articles published in our journal can be accessed online.
This document provides estimates of medical device spending in the United States from 1989-2009. The key findings are:
1) Medical devices accounted for 5.9% of total national health expenditures in 2009, totaling $147 billion. This share has remained relatively constant since 1992, ranging from 5.3-6%.
2) Medical device price increases have consistently been lower than other medical prices and inflation, averaging 1% annually compared to 4.7% for medical care prices and 2.8% for overall inflation.
3) While medical device spending has increased slightly faster than overall health spending, the constant share of total spending and slower price increases suggest medical devices have not been major drivers of rising healthcare costs in the
Reforming GxP for Today and Tomorrow- Philadelphia, PA meetingDemet G. Sag
Reforming GxP for today and tomorrow
The general issues
Imports vs Safety
Driving market & business
II. Global Impact Factors
Regulation Strategies
III. Development of Education Program &Training
Survey of likely 2014 likely voters in Arkansas, Colorado, Georgia, Kentucky, Louisiana, Michigan, Montana and North Carolina measuring opinion of the proposed EPA carbon emissions regulations.
Magellan Strategies conducted surveys in 8 battleground states to measure voter opinion on the EPA's newly proposed carbon emission regulations. The key findings show that on average, 37.3% of voters support the regulation, 47.1% oppose it, and 15.6% have no opinion. Additionally, 55.2% of respondents are more likely to oppose Senate candidates that support the regulation. When given further information on economic impacts, opposition increases to over 59%. The surveys conclude that any candidate supporting the regulation will face risks in these 2014 elections.
This report examines CMS's oversight of Medicare Part D beneficiaries who receive opioid prescriptions and providers who prescribe opioids to these beneficiaries. It finds that while CMS provides guidance to Part D plan sponsors on monitoring beneficiaries at high risk of opioid overuse, it lacks complete data on the full population of beneficiaries at risk. It also finds that CMS oversees prescribing through its contractor NBI MEDIC but does not specifically analyze opioid prescription data or require reporting on actions taken regarding inappropriate opioid prescribing. The report concludes that CMS needs more comprehensive oversight to reduce the risks of opioid misuse, overdose, and inappropriate prescribing among Medicare beneficiaries.
Summary: At The Economist’s War on Cancer 2015 event on 20 October 2015 (http://www.economist.com/events-conferences/emea/war-cancer-london), EY’s Silvia Ondategui-Parra joined the panel discussion “The patient/payer debate—balancing clinical need and affordability.” The panel explored the ongoing tension between the soaring cost of cancer drugs and governments’ ability to fund them and raised the question, do we need an entirely new pricing model? This EY infographic was developed to highlight some of the key trends driving the debate.
2014 Profile: Biopharmaceutical Research IndustryPhRMA
Biopharmaceutical science is a complex, collaborative, resource-intensive enterprise. It requires a highly skilled workforce, sustained investment, and long-term vision. Critical to its success are policies and regulations that foster innovation and broad access to new medicines. By working together—on the science, the research and the policies—we
can help ensure that medicines live up to patients’ hope for new solutions to our greatest health care challenges.
Sanofi reported results for Q3 2015 with sales growing 3.4% at constant exchange rates. Business EPS grew 6.1% at constant exchange rates. While diabetes sales declined 6.6% due to lower sales of Lantus in the US, other businesses such as Genzyme, vaccines, and Merial showed solid sales growth. Praluent was launched in the US and Europe for cholesterol treatment.
This document summarizes recent trends in pain clinic and pharmacy activity in Florida following legislation aimed at curbing prescription drug abuse:
- New pain clinic applications and openings declined sharply after 2011, suggesting the law successfully deterred new clinics. Complaints about clinics also declined significantly.
- New pharmacy applications and openings showed a slight downward trend but no systematic efforts to circumvent dispensing restrictions. Complaints about pharmacies remained high.
- Administrative closures of pain clinics steadily decreased after 2011, possibly due to fewer new clinics leading to more stable customer bases.
The trends provide evidence the legislation reduced problematic clinic activity but had little impact on pharmacies, warranting further legislative investigation of high pharmacy complaint levels.
How Do Opioid Prices and the Evolving Opioid Crisis Relate to the North Ameri...with Wind
The Role of Opioid Prices in the Evolving Opioid Crisis is a publication by order of the Commander in Chief; Our 45th President, Mr. Donald J Trump.
This is an objective purview of the role pharmaceutical marketing and advertising and the one true law that is Supply and Demand have had on the current crisis North America finds itself in.
I aim to be objective - no subjective - or opinionated argument - merely share the presentation as it was originally published by < whitehouse.gov. >
I will state this - however - the opioid crisis - is real - it is not some propaganda cooked up by CDC - DEA - or the Free Masons (wholly misunderstood by today's youth - Illuminati).
It has - in some, shape, form or fashion - affected every single North American at some point over the entirety of this - ridiculous attempt at going to war - against substances.
For my opinions, feel free to connect on
< https://www.linkedin.com/in/oudcollective >
FOLLOW @oudcollective
< https://www.twitter.com/oudcollective >
or help out in pinning beginnings at
< https://www.pinterest.com/THEWINDLLC >
Best,
< linktr.ee/C.Brennan.Poole >
< https://allmylinks.com/chasing-the-wind >
Chasing the Wind, LLC DBA THE WIND LLC is licensed under a creative commons attribution share-alike (CC BY-SA) International 4.0 license. Link to license at < www.creativecommons.org/licenses/by-sa/4.0 >
Amgen Inc. is a biotechnology/pharmaceutical company based in the US that was founded in 1980. The document provides an overview of Amgen's financial performance, acquisitions, competitors including AbbVie, Johnson & Johnson, and Celgene, and recommends Amgen as a moderately safe investment option in the biotech industry.
TRENDS AND PATTERNS OF GEOGRAPHIC VARIATIONS IN OPIOID PRESCRIBINGwith Wind
The document analyzes trends in opioid prescribing practices across US states from 2006 to 2017. It finds that while the total amount of opioids prescribed decreased over this period, the duration of prescriptions increased. Specifically:
- The total amount of opioids prescribed per person decreased 12.8% on average nationally, though there was significant variation between states.
- The mean duration of opioid prescriptions increased 37.6% nationally, with increases in every state.
- Prescriptions for durations of 30 days or longer, which are more likely to treat chronic pain, increased 37.7% nationally, with increases in 39 states.
- However, prescribing rates decreased for high dosages, short durations,
The Canadian Cancer Survivor Network is pleased to offer a webinar titled “Health Canada calls for new tools to control drug prices: what will it mean for patients?”. This webinar will summarize the various pharmaceutical pricing reforms recently announced by federal health minister Dr. Jane Philpott and examine their potential effects on patient access to new innovations.
How is drug spending affected in the year 2017Steve Martin
As per the reports published in American Journal of Health-System Pharmacy (AJHP) in the year 2016, national trends in prescription drug expenditures were projected to increase by 6 to 8% in 2017 across all healthcare settings.
Visiongain launches new report - Top 20 pharmaceutical wholesale & distributi...Visiongain
Visiongain launches new report - Top 20 pharmaceutical wholesale & distribution organizations 2018: Branded Drugs, Generic Drugs, Leading Companies
For the TOC click on : https://www.visiongain.com/report/top-20-pharmaceutical-wholesale-distribution-organizations-2018/
Please contact abhi.ambi@visiongain.com for a report overview.
This document summarizes the national perspective on prescription drug abuse in the United States. It outlines the federal government's Prescription Drug Abuse Prevention Plan, which takes a coordinated approach across four focus areas: education, prescription drug monitoring programs, proper medication disposal, and enforcement. The document also provides some statistics showing signs of progress in reducing prescription drug abuse, such as decreases in the number of Americans initiating nonmedical use of prescription opioids and in the rates of past year use among high school seniors of certain opioids. However, it notes that long-term success will require ongoing coordination across government levels.
The FOURIER trial investigated whether adding evolocumab to statin therapy reduces cardiovascular events. Over 27,000 patients with a history of cardiovascular disease were randomized to receive evolocumab or placebo injections in addition to statin therapy. The primary objective was to determine if evolocumab lowered the risk of major cardiovascular events such as heart attack, stroke, and cardiovascular death. Secondary objectives were to examine the long-term safety and tolerability of evolocumab and investigate the efficacy and safety of achieving very low LDL-cholesterol levels. Results from this outcomes trial could provide evidence on whether PCSK9 inhibition translates to clinical benefit for high-risk patients.
Thompson Dean is the Co-CEO of Avista Capital Partners, a growth investment firm focused on healthcare. One of Avista's portfolio companies is Osmotica Pharmaceuticals, which analysts expect will see 74% year-over-year revenue growth as it brings new products to market after years of research and clinical trials. Osmotica is expected to become profitable starting in 2022 after operating nearly at breakeven, as the pharmaceutical industry typically experiences irregular cash flows depending on products' development stages.
Hydraulic Fracturing Chemicals and Mixtures; Advance Notice of Proposed Rulem...Marcellus Drilling News
A notice from the federal EPA that they intend to craft new regulations requiring something already being done voluntarily--reporting of the chemicals used during hydraulic fracturing for every well drilled in the U.S. The new rule is a naked attempt at regulating oil and gas drilling in the U.s. by the federal government--something specifically left to the individual states to regulate under the U.S. Constitution. It is just one of the many attempts at violating the Constitution made by the EPA under the odious Obama administration.
The document recommends an overweight position in the healthcare biotechnology industry. Major companies are seeing double digit revenue growth and high profit margins due to limited competition from patents. However, government regulation poses a threat if it imposes price caps or reduces patent lives. Additionally, companies rely on a small number of "star drugs" whose expiration or replacement could significantly harm their value.
This document summarizes strategic factors that contributed to the success of major pharmaceutical companies ("Big Pharma") between 1995 and 2004. It finds that companies who increased their pharmaceutical focus, pursued strategic alliances and mergers/acquisitions, and maintained strong presence in key therapeutic segments ("survivors" like Novartis, Roche, GSK, Pfizer) saw higher market share growth than companies that did not employ these strategies ("stayers" and "fringers"). The survivors in particular launched more new drug molecules, spent more on lobbying, and occupied top market positions in most therapy segments.
The Food and Drug Administration Safety and Innovation Act (FDASIA) was recently signed into law by President Obama. The act has been in the works since 2004. It is seen as a strategy to level the playing field by applying a different lower-fee structure to domestic manufacturers and enforcing the same FDA inspection schedule for international facilities.
The global oilfield chemicals market is projected to grow at a CAGR of 5.7% through 2015, reaching $8.2 billion. Drilling-related chemicals currently account for 52% of the market and are expected to increase to 55-56% by 2015. The report analyzes market trends for oilfield process chemicals used in exploration, drilling, and production on a global scale, considering factors like increasing energy demand, new oil discoveries, and environmental regulations.
The document provides a profile summary of an individual with over 11 years of experience in retail banking and branch operations management. Some key points include:
- Currently working as the Branch Operations Manager at RBL Bank Ltd in Pune, managing all branch banking activities and ensuring customer satisfaction.
- Previous experience includes roles at HDFC Bank, Deutsche Bank, and Axis Bank, handling branch operations, customer relationships, and achieving sales targets.
- Educational qualifications include an MBA in Finance and Marketing and a B.E. in Mechanical Engineering.
Mercer Capital's Value Focus: Laboratory Services | Year-End 2015Mercer Capital
Mercer Capital's Laboratory Services Industry newsletter provides perspective on valuation issues. Each newsletter also includes a macroeconomic trends, industry trends, and guideline public company metrics.
Magellan Strategies conducted surveys in 8 battleground states to measure voter opinion on the EPA's newly proposed carbon emission regulations. The key findings show that on average, 37.3% of voters support the regulation, 47.1% oppose it, and 15.6% have no opinion. Additionally, 55.2% of respondents are more likely to oppose Senate candidates that support the regulation. When given further information on economic impacts, opposition increases to over 59%. The surveys conclude that any candidate supporting the regulation will face risks in these 2014 elections.
This report examines CMS's oversight of Medicare Part D beneficiaries who receive opioid prescriptions and providers who prescribe opioids to these beneficiaries. It finds that while CMS provides guidance to Part D plan sponsors on monitoring beneficiaries at high risk of opioid overuse, it lacks complete data on the full population of beneficiaries at risk. It also finds that CMS oversees prescribing through its contractor NBI MEDIC but does not specifically analyze opioid prescription data or require reporting on actions taken regarding inappropriate opioid prescribing. The report concludes that CMS needs more comprehensive oversight to reduce the risks of opioid misuse, overdose, and inappropriate prescribing among Medicare beneficiaries.
Summary: At The Economist’s War on Cancer 2015 event on 20 October 2015 (http://www.economist.com/events-conferences/emea/war-cancer-london), EY’s Silvia Ondategui-Parra joined the panel discussion “The patient/payer debate—balancing clinical need and affordability.” The panel explored the ongoing tension between the soaring cost of cancer drugs and governments’ ability to fund them and raised the question, do we need an entirely new pricing model? This EY infographic was developed to highlight some of the key trends driving the debate.
2014 Profile: Biopharmaceutical Research IndustryPhRMA
Biopharmaceutical science is a complex, collaborative, resource-intensive enterprise. It requires a highly skilled workforce, sustained investment, and long-term vision. Critical to its success are policies and regulations that foster innovation and broad access to new medicines. By working together—on the science, the research and the policies—we
can help ensure that medicines live up to patients’ hope for new solutions to our greatest health care challenges.
Sanofi reported results for Q3 2015 with sales growing 3.4% at constant exchange rates. Business EPS grew 6.1% at constant exchange rates. While diabetes sales declined 6.6% due to lower sales of Lantus in the US, other businesses such as Genzyme, vaccines, and Merial showed solid sales growth. Praluent was launched in the US and Europe for cholesterol treatment.
This document summarizes recent trends in pain clinic and pharmacy activity in Florida following legislation aimed at curbing prescription drug abuse:
- New pain clinic applications and openings declined sharply after 2011, suggesting the law successfully deterred new clinics. Complaints about clinics also declined significantly.
- New pharmacy applications and openings showed a slight downward trend but no systematic efforts to circumvent dispensing restrictions. Complaints about pharmacies remained high.
- Administrative closures of pain clinics steadily decreased after 2011, possibly due to fewer new clinics leading to more stable customer bases.
The trends provide evidence the legislation reduced problematic clinic activity but had little impact on pharmacies, warranting further legislative investigation of high pharmacy complaint levels.
How Do Opioid Prices and the Evolving Opioid Crisis Relate to the North Ameri...with Wind
The Role of Opioid Prices in the Evolving Opioid Crisis is a publication by order of the Commander in Chief; Our 45th President, Mr. Donald J Trump.
This is an objective purview of the role pharmaceutical marketing and advertising and the one true law that is Supply and Demand have had on the current crisis North America finds itself in.
I aim to be objective - no subjective - or opinionated argument - merely share the presentation as it was originally published by < whitehouse.gov. >
I will state this - however - the opioid crisis - is real - it is not some propaganda cooked up by CDC - DEA - or the Free Masons (wholly misunderstood by today's youth - Illuminati).
It has - in some, shape, form or fashion - affected every single North American at some point over the entirety of this - ridiculous attempt at going to war - against substances.
For my opinions, feel free to connect on
< https://www.linkedin.com/in/oudcollective >
FOLLOW @oudcollective
< https://www.twitter.com/oudcollective >
or help out in pinning beginnings at
< https://www.pinterest.com/THEWINDLLC >
Best,
< linktr.ee/C.Brennan.Poole >
< https://allmylinks.com/chasing-the-wind >
Chasing the Wind, LLC DBA THE WIND LLC is licensed under a creative commons attribution share-alike (CC BY-SA) International 4.0 license. Link to license at < www.creativecommons.org/licenses/by-sa/4.0 >
Amgen Inc. is a biotechnology/pharmaceutical company based in the US that was founded in 1980. The document provides an overview of Amgen's financial performance, acquisitions, competitors including AbbVie, Johnson & Johnson, and Celgene, and recommends Amgen as a moderately safe investment option in the biotech industry.
TRENDS AND PATTERNS OF GEOGRAPHIC VARIATIONS IN OPIOID PRESCRIBINGwith Wind
The document analyzes trends in opioid prescribing practices across US states from 2006 to 2017. It finds that while the total amount of opioids prescribed decreased over this period, the duration of prescriptions increased. Specifically:
- The total amount of opioids prescribed per person decreased 12.8% on average nationally, though there was significant variation between states.
- The mean duration of opioid prescriptions increased 37.6% nationally, with increases in every state.
- Prescriptions for durations of 30 days or longer, which are more likely to treat chronic pain, increased 37.7% nationally, with increases in 39 states.
- However, prescribing rates decreased for high dosages, short durations,
The Canadian Cancer Survivor Network is pleased to offer a webinar titled “Health Canada calls for new tools to control drug prices: what will it mean for patients?”. This webinar will summarize the various pharmaceutical pricing reforms recently announced by federal health minister Dr. Jane Philpott and examine their potential effects on patient access to new innovations.
How is drug spending affected in the year 2017Steve Martin
As per the reports published in American Journal of Health-System Pharmacy (AJHP) in the year 2016, national trends in prescription drug expenditures were projected to increase by 6 to 8% in 2017 across all healthcare settings.
Visiongain launches new report - Top 20 pharmaceutical wholesale & distributi...Visiongain
Visiongain launches new report - Top 20 pharmaceutical wholesale & distribution organizations 2018: Branded Drugs, Generic Drugs, Leading Companies
For the TOC click on : https://www.visiongain.com/report/top-20-pharmaceutical-wholesale-distribution-organizations-2018/
Please contact abhi.ambi@visiongain.com for a report overview.
This document summarizes the national perspective on prescription drug abuse in the United States. It outlines the federal government's Prescription Drug Abuse Prevention Plan, which takes a coordinated approach across four focus areas: education, prescription drug monitoring programs, proper medication disposal, and enforcement. The document also provides some statistics showing signs of progress in reducing prescription drug abuse, such as decreases in the number of Americans initiating nonmedical use of prescription opioids and in the rates of past year use among high school seniors of certain opioids. However, it notes that long-term success will require ongoing coordination across government levels.
The FOURIER trial investigated whether adding evolocumab to statin therapy reduces cardiovascular events. Over 27,000 patients with a history of cardiovascular disease were randomized to receive evolocumab or placebo injections in addition to statin therapy. The primary objective was to determine if evolocumab lowered the risk of major cardiovascular events such as heart attack, stroke, and cardiovascular death. Secondary objectives were to examine the long-term safety and tolerability of evolocumab and investigate the efficacy and safety of achieving very low LDL-cholesterol levels. Results from this outcomes trial could provide evidence on whether PCSK9 inhibition translates to clinical benefit for high-risk patients.
Thompson Dean is the Co-CEO of Avista Capital Partners, a growth investment firm focused on healthcare. One of Avista's portfolio companies is Osmotica Pharmaceuticals, which analysts expect will see 74% year-over-year revenue growth as it brings new products to market after years of research and clinical trials. Osmotica is expected to become profitable starting in 2022 after operating nearly at breakeven, as the pharmaceutical industry typically experiences irregular cash flows depending on products' development stages.
Hydraulic Fracturing Chemicals and Mixtures; Advance Notice of Proposed Rulem...Marcellus Drilling News
A notice from the federal EPA that they intend to craft new regulations requiring something already being done voluntarily--reporting of the chemicals used during hydraulic fracturing for every well drilled in the U.S. The new rule is a naked attempt at regulating oil and gas drilling in the U.s. by the federal government--something specifically left to the individual states to regulate under the U.S. Constitution. It is just one of the many attempts at violating the Constitution made by the EPA under the odious Obama administration.
The document recommends an overweight position in the healthcare biotechnology industry. Major companies are seeing double digit revenue growth and high profit margins due to limited competition from patents. However, government regulation poses a threat if it imposes price caps or reduces patent lives. Additionally, companies rely on a small number of "star drugs" whose expiration or replacement could significantly harm their value.
This document summarizes strategic factors that contributed to the success of major pharmaceutical companies ("Big Pharma") between 1995 and 2004. It finds that companies who increased their pharmaceutical focus, pursued strategic alliances and mergers/acquisitions, and maintained strong presence in key therapeutic segments ("survivors" like Novartis, Roche, GSK, Pfizer) saw higher market share growth than companies that did not employ these strategies ("stayers" and "fringers"). The survivors in particular launched more new drug molecules, spent more on lobbying, and occupied top market positions in most therapy segments.
The Food and Drug Administration Safety and Innovation Act (FDASIA) was recently signed into law by President Obama. The act has been in the works since 2004. It is seen as a strategy to level the playing field by applying a different lower-fee structure to domestic manufacturers and enforcing the same FDA inspection schedule for international facilities.
The global oilfield chemicals market is projected to grow at a CAGR of 5.7% through 2015, reaching $8.2 billion. Drilling-related chemicals currently account for 52% of the market and are expected to increase to 55-56% by 2015. The report analyzes market trends for oilfield process chemicals used in exploration, drilling, and production on a global scale, considering factors like increasing energy demand, new oil discoveries, and environmental regulations.
The document provides a profile summary of an individual with over 11 years of experience in retail banking and branch operations management. Some key points include:
- Currently working as the Branch Operations Manager at RBL Bank Ltd in Pune, managing all branch banking activities and ensuring customer satisfaction.
- Previous experience includes roles at HDFC Bank, Deutsche Bank, and Axis Bank, handling branch operations, customer relationships, and achieving sales targets.
- Educational qualifications include an MBA in Finance and Marketing and a B.E. in Mechanical Engineering.
Mercer Capital's Value Focus: Laboratory Services | Year-End 2015Mercer Capital
Mercer Capital's Laboratory Services Industry newsletter provides perspective on valuation issues. Each newsletter also includes a macroeconomic trends, industry trends, and guideline public company metrics.
A qualitative analysis of South African women's knowledge, attitudes and beli...Michele Battle-Fisher
Francis, S., Battle-Fisher, M.#, Liverpool, J., Hipple, L., Mosavel, M., Shogun, S.,
& Mofammere, M. (2011) A qualitative analysis of South African women's knowledge, attitudes, and beliefs about HPV and cervical cancer prevention,
vaccine awareness and acceptance, and maternal-child communication about sexual health. Vaccine, 29, 8760-8765.
El documento define cinco tipos de conceptos relacionados con sistemas informáticos: hardware, que se refiere a las partes físicas de un sistema como componentes eléctricos y electrónicos; bienestar, que se refiere al estado mental y emocional del usuario; conectividad, que se refiere al sistema que permite la conexión a Internet; software, que se refiere a los programas que gestionan los recursos del hardware; y usuario, que se refiere a la persona que usa el sistema.
Boston Beer Company (SAM) is recommended as a buy based on its position in the growing craft beer industry. SAM has successfully introduced new flavorful beer brands to the market, fueling revenue growth of 13.5% in 2015 and projected annual growth of 5.5% through 2020. This positions SAM well to benefit from industry expansion. Some risks include potential slowing of flagship brand sales growth and increased competition from spirits. Valuation models yield a target price of $218-$220, indicating 9% upside potential.
In this file, you can ref useful information about performance appraisal of wipro such as performance appraisal of wipro methods, performance appraisal of wipro tips
Verizon was formed in 2000 through the merger of Bell Atlantic Corp and GTE Corp. It is currently the largest telecommunications company in the US. Verizon's mission is to use technology to solve problems in education, healthcare, and energy management. One of its strategic recommendations is to expand its wireless services into the Canadian market through acquiring carriers like Wind Mobile and Mobilicity. This would help increase profits and give Verizon an international presence, but would also increase its current debt.
Quest Diagnostics acquired SmithKline Beecham Clinical Laboratories in 1999, making it the clear leader in diagnostic testing in the US. Net income excluding special items was $41.2 million in 1999 compared to $26.9 million in 1998 due to the acquisition. However, after special items related to the acquisition, the company reported a net loss of $3.4 million. The company's strategy is focused on capitalizing on its position in diagnostic testing, becoming a leading provider of medical information by leveraging its large database of test results, and becoming recognized as the quality leader in healthcare services.
The document analyzes Deere & Company (DE), a global manufacturer of agricultural and construction equipment. It recommends a HOLD rating for DE stock, with a target price of $84.59. While DE's brand recognition in the US and Canada will support market share gains, the company faces downward trends in foreign markets and declining margins. A DCF analysis indicates the stock is currently slightly overvalued. Key risks to the business include government regulation, economic slowdowns, and currency fluctuations.
The document is the balance sheet of Wipro Infrastructure Engineering AB as of March 31, 2010. It shows that the company had total assets of Rs. 3,837,499,823, with fixed assets accounting for Rs. 736,891,925 of this amount. Total liabilities were Rs. 1,992,491,932 in shareholder funds and Rs. 1,845,007,891 in loan funds. Net current assets were Rs. 1,826,988,211.
LabCorp is a leading healthcare services company focused on clinical diagnostics and personalized medicine. It has a strong market position due to factors such as an aging population driving increased testing, healthcare reform promoting value-based care, and advances in genomics enabling personalized treatment. LabCorp pursues a five pillar strategy of capital deployment, enhancing IT capabilities, improving efficiency, innovating scientifically, and developing knowledge services to execute its mission and create shareholder value. It aims to be a trusted knowledge partner for stakeholders across the healthcare continuum.
A phosphoric acid fuel cell has two porous electrodes that collect charge - a negative electrode of hydrogen gas and a positive electrode of oxygen or air. Phosphoric acid acts as the electrolyte, and platinum catalysts on both electrodes accelerate the electrochemical reactions. Hydrogen ions migrate through the electrolyte to the positive electrode, where they interact with oxygen to produce water, while electrons flow through an external load to provide electricity. The fuel cell operates between 150-200 degrees Celsius and has an actual voltage of 0.7-0.8 volts, lower than its theoretical potential of 1.23 volts.
This document provides a summary of a financial analysis of Pfizer conducted by Riley Bannon and Dylan Murphy. It includes an executive summary, purpose, methodology, economic analysis, industry forecast, analysis of Pfizer's competition and business, and conclusions and recommendations. The economic analysis forecasts modest GDP growth of around 2.8% annually through 2018, a declining unemployment rate, and gradual interest rate increases. The industry forecast expects continued strong demand for pharmaceuticals driven by an aging population, though tempered growth due to potential increased regulation. The document analyzes Pfizer's financials, business strategy, valuation, and competition to make an investment recommendation.
John Deere's bids on tractor components were higher than competitors due to issues with its cost accounting system. The current system allocated fixed costs like engineering and setup costs across all orders equally, regardless of order size. This led to underestimating costs for low-volume orders and overestimating costs for high-volume orders. Switching to an activity-based costing (ABC) system would improve accuracy by allocating costs based on demand each product places on activities. This would allow John Deere to submit more competitive bids and improve profitability by focusing on high-volume orders it has an efficiency advantage in.
The value of early asset development and commercializationCello Health
Worldwide pharmaceutical R&D spend is increasing each year, and the competition for a share of that investment is becoming fiercer. Companies need to demonstrate the potential value of their asset in commercial as well as scientific and clinical terms.
The slides in this deck define and identify value from a financial, clinical and commercial perspective while also exploring how to derive value for patients.
The document provides an overview of key findings from a survey of the Australian biotechnology industry in 2015. Some of the main points include:
- Business sentiment in the industry remains strong despite views that the operating environment is challenging. 69% reported having a good year in 2014 and 84% expect to grow in 2015.
- Access to capital continues to be important, with 48% looking to raise funds in the coming year and 34% having less than one year of cash.
- The industry is expected to create at least 239 new jobs in 2015 focusing on scientists, clinical trials, and advanced manufacturing roles.
- Tax policy is a major concern for companies, though the R&D tax incentive remains an
Future Challenges of Clinical Development; a View from the CRO - Hani ZakiTTC, llc
The document discusses current challenges and future trends in clinical development from the perspective of a CRO. It notes that the global CRO market is large but fragmented, and outlines pressures on the pharmaceutical industry like high R&D costs, patent expirations, and regulatory demands. The text also examines trends towards more global, efficient trials using new technologies and less traditional geographies to address these challenges. It argues that collaboration between industry, regulators and CROs will be key to transforming clinical research methods.
Future Challenges of Clinical Development; a View from the CRO - Hani ZakiTTC, llc
The document discusses current challenges and future trends in clinical development from the perspective of a CRO. It notes that the global CRO market is large but fragmented, and outlines pressures on the pharmaceutical industry like high R&D costs, patent expirations, and regulatory demands. The text also examines trends towards more global, efficient trials using new technologies and less traditional geographies to address these challenges. It argues that collaboration between industry, regulators and CROs will be key to transforming clinical research processes to increase competitiveness and innovation.
Catalent is the global leader in drug development and manufacturing. It has over 1,300 patents and is well-positioned to benefit from substantial industry growth of 6-10% annually through 2020. While pricing pressures could slow industry growth, Catalent's business model focusing on development, delivery, and supply solutions provides long-term stable revenues. The recommendation is to buy Catalent stock, which trades at $29.13 but has a target price of $35.99 based on discounted cash flow analysis.
Medical Instrument and Supply Manufacturing Industry ReportCharles Pontrelli
The document provides an overview of the medical instrument and supply manufacturing industry. It discusses key factors such as an aging population driving increased demand, regulations from the FDA and PPACA, and consolidation in the industry with larger companies acquiring smaller innovative ones. While the industry faces pressures from regulations and increasing wages, overall growth is expected to continue due to demographic trends and the need for ongoing innovation in medical technology. The industry provides opportunities for Oregon companies if they maintain innovation and low costs.
Biopharma Informatic, Inc. is a site management organization (SMO) that recruits patients and physicians for clinical trials on behalf of pharmaceutical companies and contract research organizations. As an SMO, it facilitates clinical research by finding suitable trial locations and participants. The company aims to establish a nationwide network and expand globally to meet increasing demand from clients in the rapidly growing clinical research industry.
The document summarizes perspectives from a panel of finance directors on successful collaborations in the biopharmaceutical industry. The panel emphasizes clear communication, understanding partners' perspectives, resolving disputes internally, and adhering to collaboration agreements while considering real-world flexibility. It also provides examples of specific company collaborations and financial arrangements.
The contract research organization (CRO) industry is a multi-billion dollar industry that is expected to grow substantially over the next five years. There are over 1,000 CROs globally, ranging in size from small firms to large publicly traded companies. The top five CROs capture over a third of total industry revenue, suggesting market consolidation. Growth in the industry is driven by increasing complexity and size of clinical trials, globalization of drug development, and pharmaceutical industry cost containment pressures that encourage further outsourcing of services.
Analysis of drivers that cause restricted access to funding for smaller biotech companies.
A detailed reviewed of the steps
venture capitalists and companies are
taking — models such as fail-fast R&D, asset-centric funding and more.
Proposal of a model that
could radically change R&D by taking a
much more holistic approach to drug
development, sharing information to
learn in real time across the cycle of care
and fundamentally changing how risk
and reward are allocated.
The document outlines the opportunities and challenges presented by big data in healthcare. It notes that vast amounts of data are now being generated from sources like genome sequencing, electronic health records, social media, and patient websites. However, simply having large datasets does not guarantee value; the data needs to be analyzed and linked together to generate insights. The document discusses four levels of big data applications from processing large volumes of data to complex modeling. It also examines challenges like developing robust governance, embracing new data uses, overcoming data fragmentation, ensuring data quality and standards, developing innovative analytic methods, addressing skills shortages, and achieving returns on investment. The goal is to improve patient outcomes and healthcare cost-effectiveness through big data.
The biotechnology industry had an unprecedented year in 2014, reaching new highs in revenues, R&D spending, profits, financing amounts, and market capitalization. Strong product sales and approvals helped boost investor sentiment and company valuations. A surge in IPOs and follow-on financings provided the industry with historic levels of capital to fund innovation.
The document discusses initiatives by the Government of India to promote research and development in the pharmaceutical sector. It provides details about the Drugs and Pharmaceuticals Research Programme (DPRP) launched by the Department of Science and Technology. DPRP aims to enhance capabilities of the Indian drugs industry through public-private partnerships. It provides grants and soft loans to support collaborative R&D projects between public institutions and industry. Over 50 industry-institutional alliances have been formed under this program.
The removal of the price on carbon led to the collapse of the
Australian carbon-trading sector and deliberate regulatory
uncertainty for renewable energy projects has stifled
investment in large-scale renewable energy projects, as
demonstrated by Bloomberg New Energy Finance statistics
which reveal an 88 per cent drop in large-scale clean energy
investment in 2014 compared to 2013.
While car-makers suffered, among other factors, from
Australia’s failure to introduce fuel efficiency regulations,
other businesses have prospered from the introduction
of smart regulations, such as water trading and efficiency
policies. Spurred to innovate, Australian businesses are
now competing internationally by exporting water-efficient
products and know-how to major markets like California
and Brazil.
Australia’s economy is highly exposed to global economic
changes. Government regulation, whether local or
overseas, will often have strong flow-on effects for the local
economy.
The overall global trend is for governments to regulate
markets when they fail to account for costly environmental
side-effects (externalities). This has already been observed
with the ongoing roll-out of national and regional carbon
prices around the world.
Other regulations are being adapted to boost the trade in more sustainable products, as observed in 2014 with Asia Pacific
Economic Cooperation (APEC) commitment to free trade in environmental goods. Regardless of government decisions
made in Australia, government regulation in other countries will continue to increase the breadth and size of the export
market for more sustainable products and services. But there is a risk that the lack of proactive national regulation will
undermine Australia’s brand strength on sustainability and limit local businesses’ ability to compete in this growing market.
BD is a leading global medical technology company that reported strong financial and operational results in its 2008 Annual Report. Revenues increased 12.5% to $7.15 billion and income from continuing operations increased 31.7% to $1.12 billion. BD invested in innovation and growth initiatives while returning over $700 million to shareholders in share repurchases and dividends. The company aims to improve global health through initiatives that reduce infection, advance therapy and disease management. In 2008, BD associates volunteered in Ghana and Uganda to strengthen healthcare systems and laboratory services.
BD is a leading global medical technology company that reported strong financial and operational results in its 2008 Annual Report. Revenues increased 12.5% to $7.15 billion and income from continuing operations increased 31.7% to $1.12 billion. BD invested in innovation and growth initiatives while returning over $700 million to shareholders in share repurchases and dividends. The company aims to improve global health through initiatives that reduce infection, advance therapy and disease management. In 2008, BD associates volunteered in Ghana and Uganda to strengthen healthcare systems and laboratory services.
BD is a leading global medical technology company that reported strong financial and operational results in its 2008 Annual Report. Revenues increased 12.5% to $7.15 billion and income from continuing operations increased 31.7% to $1.12 billion. BD invested in innovation and growth initiatives while returning over $700 million to shareholders in share repurchases and dividends. The company aims to improve global health through initiatives that reduce infection, advance therapy and disease management.
BD is a leading global medical technology company that reported strong financial and operational results in its 2008 Annual Report. Revenues increased 12.5% to $7.15 billion and income from continuing operations increased 31.7% to $1.12 billion. BD invested in innovation and growth initiatives while returning over $700 million to shareholders in share repurchases and dividends. The company aims to improve global health through initiatives that reduce infection, advance therapy and disease management.
The document summarizes a presentation on climate change and the healthcare sector. It discusses how healthcare accounts for 3-5% of global greenhouse gas emissions and 8-12% of emissions in the US. Future trends like population growth and increased healthcare spending could significantly increase emissions if not addressed. The presentation covers initiatives to measure and reduce emissions, including the GHG Protocol standards, NHS carbon footprint guidance for pharmaceuticals and medical devices, and case studies of healthcare organizations implementing reduction strategies.
This document is an investor presentation by Invitae Corporation, which aims to bring genetic information into mainstream medical practice by providing affordable and comprehensive genetic testing. It summarizes Invitae's business model of offering testing for thousands of genes at one price regardless of quantity. The presentation outlines Invitae's growth in testing volume and covered lives, improvement in costs per test, and expansion of genetic content. It envisions building genetic testing, genome management, and a genome network into a platform for long-term growth in individual and population health.
Similar to Mercer Capital's Value Focus: Laboratory Services | Mid-Year 2015 (20)
Mercer Capital's Bank Watch | September 2023 | The Interest Rate Environment ...Mercer Capital
Brought to you by the Financial Institutions Team of Mercer Capital, this monthly newsletter is focused on bank activity in five U.S. regions. Bank Watch highlights various banking metrics, including public market indicators, M&A market indicators, and key indices of the top financial institutions, providing insight into financial institution valuation issues.
Mercer Capital's Investment Management Industry Newsletter | Q2 2023 | Focus:...Mercer Capital
Mercer Capital’s Investment Management Industry newsletter is a quarterly publication providing perspective on valuation issues pertinent to asset managers, trust companies, and investment consultants.
Mercer Capital's Bank Watch | July 2023 | Bank Impairment TestingMercer Capital
Brought to you by the Financial Institutions Team of Mercer Capital, this monthly newsletter is focused on bank activity in five U.S. regions. Bank Watch highlights various banking metrics, including public market indicators, M&A market indicators, and key indices of the top financial institutions, providing insight into financial institution valuation issues.
Mercer Capital's Value Focus: Transportation & Logistics | Q1 2023 |Mercer Capital
Mercer Capital's Transportation & LogisticsIndustry newsletter provides perspective on valuation issues. Each newsletter also typically includes macroeconomic trends, industry trends, mergers and acquisitions review, and guideline public company metrics.
Mercer Capital's Value Matters™ | Issue No. 1, 2023 Mercer Capital
Mercer Capital's Value Matters™, addresses gift & estate tax, ESOP, buy-sell agreement, and transaction advisory topics of interest to estate planners and other professional advisors to business.
Mercer Capital - Corporate Finance in 30 Minutes Whitepaper.pdfMercer Capital
Corporate finance does not need to be a mystery. In this whitepaper, we distill the
fundamental principles of corporate finance into an accessible and non-technical
primer. Structured around the three key decisions of capital structure, capital
budgeting, and distribution policy, the guide is designed to assist family business directors and shareholders without a finance background make relevant and
meaningful contributions to the most consequential financial decisions all companies must make. Our goal with this whitepaper is to give family business directors
and shareholders a vocabulary and conceptual framework for thinking about strategic corporate finance decisions, allowing them to bring their perspectives and
expertise to the discussion.
Mercer Capital's Bank Watch | March 2023 | “I’m Not Broke. I’m Just Not Liquid.”Mercer Capital
Brought to you by the Financial Institutions Team of Mercer Capital, this monthly newsletter is focused on bank activity in five U.S. regions. Bank Watch highlights various banking metrics, including public market indicators, M&A market indicators, and key indices of the top financial institutions, providing insight into financial institution valuation issues.
Mercer Capital's Bank Watch | February 2023 | Themes from Bank Director’s 202...Mercer Capital
Brought to you by the Financial Institutions Team of Mercer Capital, this monthly newsletter is focused on bank activity in five U.S. regions. Bank Watch highlights various banking metrics, including public market indicators, M&A market indicators, and key indices of the top financial institutions, providing insight into financial institution valuation issues.
Mercer Capital's Investment Management Industry Newsletter | Q4 2023 | Focus:...Mercer Capital
Mercer Capital’s Investment Management Industry newsletter is a quarterly publication providing perspective on valuation issues pertinent to asset managers, trust companies, and investment consultants.
Mercer Capital's Value Focus: Exploration and Production | Fourth Quarter 202...Mercer Capital
Mercer Capital's Energy Industry newsletter provides perspective on valuation issues. Each newsletter also typically includes a macroeconomic trends, industry trends, and guideline public company metrics.
Mercer Capital's Bank Watch | December 2022 | Bank M&A 2022 - TurbulenceMercer Capital
Brought to you by the Financial Institutions Team of Mercer Capital, this monthly newsletter is focused on bank activity in five U.S. regions. Bank Watch highlights various banking metrics, including public market indicators, M&A market indicators, and key indices of the top financial institutions, providing insight into financial institution valuation issues.
Mercer Capital's Value Matters™ | Issue No. 3, 2022|Mercer Capital
Mercer Capital's Value Matters™, published 6 times per year, addresses gift & estate tax, ESOP, buy-sell agreement, and transaction advisory topics of interest to estate planners and other professional advisors to business.
Mercer Capital's Value Focus: Transportation & Logistics | Q3 2022 Mercer Capital
Mercer Capital's Transportation & LogisticsIndustry newsletter provides perspective on valuation issues. Each newsletter also typically includes macroeconomic trends, industry trends, mergers and acquisitions review, and guideline public company metrics.
Mercer Capital's Bank Watch | November 2022 | Community Bank Loan Portfolios ...Mercer Capital
Brought to you by the Financial Institutions Team of Mercer Capital, this monthly newsletter is focused on bank activity in five U.S. regions. Bank Watch highlights various banking metrics, including public market indicators, M&A market indicators, and key indices of the top financial institutions, providing insight into financial institution valuation issues.
Mercer Capital's Investment Management Industry Newsletter | Q3 2022 | Focus:...Mercer Capital
Mercer Capital’s Investment Management Industry newsletter is a quarterly publication providing perspective on valuation issues pertinent to asset managers, trust companies, and investment consultants.
Mercer Capital's Investment Management Industry Newsletter | Q2 2022 | Segmen...Mercer Capital
Mercer Capital’s Investment Management Industry newsletter is a quarterly publication providing perspective on valuation issues pertinent to asset managers, trust companies, and investment consultants.
Mercer Capital's Bank Watch | October 2022 | How Are Tech-Forward Banks Perfo...Mercer Capital
Brought to you by the Financial Institutions Team of Mercer Capital, this monthly newsletter is focused on bank activity in five U.S. regions. Bank Watch highlights various banking metrics, including public market indicators, M&A market indicators, and key indices of the top financial institutions, providing insight into financial institution valuation issues.
Mercer Capital's Value Focus: Transportation & Logistics | Q2 2022 | Feature...Mercer Capital
Mercer Capital's Transportation & LogisticsIndustry newsletter provides perspective on valuation issues. Each newsletter also typically includes macroeconomic trends, industry trends, mergers and acquisitions review, and guideline public company metrics.
1. Elemental Economics - Introduction to mining.pdfNeal Brewster
After this first you should: Understand the nature of mining; have an awareness of the industry’s boundaries, corporate structure and size; appreciation the complex motivations and objectives of the industries’ various participants; know how mineral reserves are defined and estimated, and how they evolve over time.
2. Elemental Economics - Mineral demand.pdfNeal Brewster
After this second you should be able to: Explain the main determinants of demand for any mineral product, and their relative importance; recognise and explain how demand for any product is likely to change with economic activity; recognise and explain the roles of technology and relative prices in influencing demand; be able to explain the differences between the rates of growth of demand for different products.
Independent Study - College of Wooster Research (2023-2024) FDI, Culture, Glo...AntoniaOwensDetwiler
"Does Foreign Direct Investment Negatively Affect Preservation of Culture in the Global South? Case Studies in Thailand and Cambodia."
Do elements of globalization, such as Foreign Direct Investment (FDI), negatively affect the ability of countries in the Global South to preserve their culture? This research aims to answer this question by employing a cross-sectional comparative case study analysis utilizing methods of difference. Thailand and Cambodia are compared as they are in the same region and have a similar culture. The metric of difference between Thailand and Cambodia is their ability to preserve their culture. This ability is operationalized by their respective attitudes towards FDI; Thailand imposes stringent regulations and limitations on FDI while Cambodia does not hesitate to accept most FDI and imposes fewer limitations. The evidence from this study suggests that FDI from globally influential countries with high gross domestic products (GDPs) (e.g. China, U.S.) challenges the ability of countries with lower GDPs (e.g. Cambodia) to protect their culture. Furthermore, the ability, or lack thereof, of the receiving countries to protect their culture is amplified by the existence and implementation of restrictive FDI policies imposed by their governments.
My study abroad in Bali, Indonesia, inspired this research topic as I noticed how globalization is changing the culture of its people. I learned their language and way of life which helped me understand the beauty and importance of cultural preservation. I believe we could all benefit from learning new perspectives as they could help us ideate solutions to contemporary issues and empathize with others.
Abhay Bhutada Leads Poonawalla Fincorp To Record Low NPA And Unprecedented Gr...Vighnesh Shashtri
Under the leadership of Abhay Bhutada, Poonawalla Fincorp has achieved record-low Non-Performing Assets (NPA) and witnessed unprecedented growth. Bhutada's strategic vision and effective management have significantly enhanced the company's financial health, showcasing a robust performance in the financial sector. This achievement underscores the company's resilience and ability to thrive in a competitive market, setting a new benchmark for operational excellence in the industry.
Financial Assets: Debit vs Equity Securities.pptxWrito-Finance
financial assets represent claim for future benefit or cash. Financial assets are formed by establishing contracts between participants. These financial assets are used for collection of huge amounts of money for business purposes.
Two major Types: Debt Securities and Equity Securities.
Debt Securities are Also known as fixed-income securities or instruments. The type of assets is formed by establishing contracts between investor and issuer of the asset.
• The first type of Debit securities is BONDS. Bonds are issued by corporations and government (both local and national government).
• The second important type of Debit security is NOTES. Apart from similarities associated with notes and bonds, notes have shorter term maturity.
• The 3rd important type of Debit security is TRESURY BILLS. These securities have short-term ranging from three months, six months, and one year. Issuer of such securities are governments.
• Above discussed debit securities are mostly issued by governments and corporations. CERTIFICATE OF DEPOSITS CDs are issued by Banks and Financial Institutions. Risk factor associated with CDs gets reduced when issued by reputable institutions or Banks.
Following are the risk attached with debt securities: Credit risk, interest rate risk and currency risk
There are no fixed maturity dates in such securities, and asset’s value is determined by company’s performance. There are two major types of equity securities: common stock and preferred stock.
Common Stock: These are simple equity securities and bear no complexities which the preferred stock bears. Holders of such securities or instrument have the voting rights when it comes to select the company’s board of director or the business decisions to be made.
Preferred Stock: Preferred stocks are sometime referred to as hybrid securities, because it contains elements of both debit security and equity security. Preferred stock confers ownership rights to security holder that is why it is equity instrument
<a href="https://www.writofinance.com/equity-securities-features-types-risk/" >Equity securities </a> as a whole is used for capital funding for companies. Companies have multiple expenses to cover. Potential growth of company is required in competitive market. So, these securities are used for capital generation, and then uses it for company’s growth.
Concluding remarks
Both are employed in business. Businesses are often established through debit securities, then what is the need for equity securities. Companies have to cover multiple expenses and expansion of business. They can also use equity instruments for repayment of debits. So, there are multiple uses for securities. As an investor, you need tools for analysis. Investment decisions are made by carefully analyzing the market. For better analysis of the stock market, investors often employ financial analysis of companies.
OJP data from firms like Vicinity Jobs have emerged as a complement to traditional sources of labour demand data, such as the Job Vacancy and Wages Survey (JVWS). Ibrahim Abuallail, PhD Candidate, University of Ottawa, presented research relating to bias in OJPs and a proposed approach to effectively adjust OJP data to complement existing official data (such as from the JVWS) and improve the measurement of labour demand.
Sources of Revenue for State Government - Prof Oyedokun.pptx
Mercer Capital's Value Focus: Laboratory Services | Mid-Year 2015
1. VALUE FOCUS
Laboratory Services Industry
www.mercercapital.com
Executive Summary Inside
The Laboratory Services industry has experi-
enced favorable performance over the last five
years as the industry’s revenue increased at an
average annual rate of 2.3% between 2010 and
2015, reaching an estimated $17.1 billion in 2015.
As defined by IBIS World, the laboratory ser-
vices industry comprises the following segments:
Product Performance & Safety Testing (42.6%),
Product Certification (27.2%), Environmental
Testing (14.9%), Agriculture & Food Testing (7.0%),
Biological and Chemical Testing (6.3%), Other
(2.0%). In addition to these segments, we will also
focus on medical testing laboratories.
The industry’s performance is sensitive to changes
in the general economic environment both inside
the U.S. and internationally. General economic
conditions may impact demand for products and
services which, in turn, trigger demand for labora-
tory services. Most recently, the industry has been
the beneficiary of increasing environmental, indus-
trial, and medical regulatory standards promoting
demand for lab services. In addition to expanding
regulatory regimes, influential growth factors
include the aging population, industry consolida-
tion, pharmacogenomics/companion diagnostics,
cost pressures, and regulation.
Mid-Year 2015
Industry Specific
Macroeconomic Overview 1
MA Transactions 3
Guideline Company Pricing 6
Valuation Trends 7
Macroeconomic Overview 9
About Mercer Capital 12
Erickson Partners
Merges with Mercer Capital 13
14. Erickson Partners
Merges with Mercer Capital
Mercer Capital, a national business valuation and financial advisory firm specializing in Cor-
porate Valuation, Litigation Support, Financial Reporting Valuation, and Transaction Advisory
Consulting, and Erickson Partners, Inc., a Texas-based Valuation and Litigation Support firm,
announce their merger effective July 1, 2015.
Mercer Capital, with its strong presence throughout the Southeast and Midwest, and Erickson
Partners, with its strong presence in Texas and Oklahoma, are a perfect fit.
Both firms maintain the highest standards of quality for financial analysis and client service and
believe deeply in hiring and developing the best professionals.
“The culture of both firms is so similar and that was important to us. The professionals of Er-
ickson Partners are well-known in the valuation profession as some of the best and brightest.
Their work product and reputation are stellar. This merger not only allows us to broaden our
geographic reach but also our industry expertise,” said Matt Crow, President of Mercer Capital.
Erickson Partners enhances Mercer Capital’s broad base of industry concentrations with their
exceptional history working with and knowledge of professional sports franchises and the en-
ergy sector.
“Over our 30 plus year history, Mercer Capital has developed several industry concentrations. By
adding the knowledge, insight, and expertise of Don Erickson, Bryce Erickson, and the rest of the
professionals of Erickson Partners, we now bring deep experience and insight to a broader range
of industries than we could as separate firms,” said Chris Mercer, CEO of Mercer Capital.
“Combining with Mercer Capital, we will now be able to offer new or expanded services that
complement our existing services, as well as additional industry expertise,” said Bryce Erick-
son, Managing Director of Erickson Partners. “In addition to our sports franchise and energy
industry concentrations, we will be able to offer deep industry concentrations in construction
and building materials, agribusiness, manufacturing and financial institutions, which includes
depository institutions, insurance companies, fintech companies, asset management firms, and
PE firms.”
“The combined firm will have over 40 valuation professionals positioned in five markets through-
out the southwest and southeast. Such a deep bench will provide us with a tremendous op-
portunity to better serve the expanding needs of our clients,” said Don Erickson, President of
Erickson Partners. “Joining with Mercer Capital gives us national resources that will benefit our
clients in Texas and beyond.”
About Mercer Capital
Mercer Capital is a national business valuation and financial advisory firm offering corporate valua-
tion, litigation support, financial reporting valuation, and transaction advisory consulting services to
a national client base. Clients include private and public operating companies, financial institutions,
asset holding companies, high-net worth families, and private equity/hedge funds.
About Erickson Partners, Inc.
Erickson Partners is a professional valuation and advisory firm specializing in business valuation,
litigation support, financial investigations and strategic corporate advisory services. Founded by
Don Bryce Erickson, Erickson Partners has served large and small clients by providing complex
financial and economic analysis, leading to reasonable valuation opinions that withstand scrutiny.
BUSINESS VALUATION
FINANCIAL ADVISORY SERVICES
CONTACT US
Z. Christopher Mercer, ASA, CFA, ABAR
901.685.2120
mercerc@mercercapital.com
Matthew R. Crow, CFA, ASA
901.685.2120
crowm@mercercapital.com
Donald Erickson, ASA
214.468.8400
ericksond@mercercapital.com
Bryce Erickson, ASA, MRICS
214.468.8400
ericksonb@mercercapital.com
MERCER CAPITAL
Headquarters
5100 Poplar Avenue, Suite 2600
Memphis, TN 38137
901.685.2120
Dallas
12201 Merit Drive, Suite 480
Dallas, TX 75251
214.468.2120
Nashville
102 Woodmont Blvd., Suite 231
Nashville, TN 37205
615.345.0350
www.mercercapital.com
COMBINING
CULTURES OF
EXCELLENCE